News
Important Only
Highpeak Energy, Inc. Announces Proposed Aggregate $725 Million Private Offering Of Senior Notes
Highpeak Energy Inc HPK.O:HIGHPEAK ENERGY, INC. ANNOUNCES PROPOSED AGGREGATE $725 MILLION PRIVATE OFFERING OF SENIOR NOTESHIGHPEAK ENERGY INC - TO OFFER $725 MILLION SENIOR NOTES DUE 2030Reuters
Mon, Jun 30
Unity Biotechnology Inc - Board Approves Plan Of Dissolution - SEC Filing
UNITY Biotechnology Inc UBX.O:UNITY BIOTECHNOLOGY INC - BOARD APPROVES PLAN OF DISSOLUTION - SEC FILINGUNITY BIOTECHNOLOGY INC - ANIRVAN GHOSH STEPS DOWN AS CEO OF UNITY BIOTECHNOLOGY - SEC FILINGUNITY BIOTECHNOLOGY INC - LYNNE SULLIVAN STEPS DOWN AS CFO OF UNITY BIOTECHNOLOGY - SEC FILINGUNITY BIOT...Reuters
Mon, Jun 30
23AndMe Receives Court Approval For Sale To TTAM Research Institute, A Nonprofit Public Benefit Corporation
June 30 (Reuters) - 23andMe Holding Co MEHCQ.PK:23ANDME RECEIVES COURT APPROVAL FOR SALE TO TTAM RESEARCH INSTITUTE, A NONPROFIT PUBLIC BENEFIT CORPORATION23ANDME - TTAM WILL ACQUIRE SUBSTANTIALLY ALL OF ASSETS OF 23ANDME FOR A PURCHASE PRICE OF $305 MILLION.Reuters
Mon, Jun 30
The Home Depot Enters Into Agreement For Srs Distribution To Acquire Gms
Home Depot Inc HD.N:THE HOME DEPOT ENTERS INTO AGREEMENT FOR SRS DISTRIBUTION TO ACQUIRE GMSHOME DEPOT INC - DEAL VALUED AT $5.5 BILLION, $110 PER SHAREHOME DEPOT INC - DEAL FUNDED THROUGH CASH AND DEBTHOME DEPOT INC - DEAL EXPECTED TO BE ACCRETIVE TO EPS IN FIRST YEARReuters
Mon, Jun 30
U Power Enters Macau Market Signs Of Its First Electric Service Provider ("ESP") Agreement In Macau
June 30 (Reuters) - U Power Ltd UCAR.O:U POWER ENTERS MACAU MARKET; SIGNS OF ITS FIRST ELECTRIC SERVICE PROVIDER ("ESP") AGREEMENT IN MACAUU POWER LTD: OVER 3 YRS, ESP PARTNER EXPECTS TO BE BUYING, SELLING ABOUT 600 FOUR-WHEELED AND 5,000 TWO-WHEELED VEHICLESReuters
Mon, Jun 30
Tyra Biosciences Doses First Patient In Phase 2 Study Of Tyra-300 In Low-Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer (Surf302)
Tyra Biosciences Inc TYRA.O:TYRA BIOSCIENCES DOSES FIRST PATIENT IN PHASE 2 STUDY OF TYRA-300 IN LOW-GRADE INTERMEDIATE RISK NON-MUSCLE INVASIVE BLADDER CANCER (SURF302)TYRA BIOSCIENCES INC - INITIAL 3-MONTH CR DATA EXPECTED IN 1H 2026Reuters
Mon, Jun 30
Avant Technologies And JV Partner, Ainnova, Prepare For Key FDA Milestone With Next Week's Pre-Submission Meeting
Avant Technologies Inc AVAI.PK:AVANT TECHNOLOGIES AND JV PARTNER, AINNOVA, PREPARE FOR KEY FDA MILESTONE WITH NEXT WEEK'S PRE-SUBMISSION MEETINGAVANT TECHNOLOGIES INC - FDA PRE-SUBMISSION MEETING SET FOR JULY 7Reuters
Mon, Jun 30
Intensity Therapeutics, Inc. Announces That Int230-6 Achieved 100% Complete Response Rate In Preclinical Models Of Malignant Peripheral Nerve Sheath Tumors (Mpnst)
Intensity Therapeutics Inc INTS.O:INTENSITY THERAPEUTICS, INC. ANNOUNCES THAT INT230-6 ACHIEVED 100% COMPLETE RESPONSE RATE IN PRECLINICAL MODELS OF MALIGNANT PERIPHERAL NERVE SHEATH TUMORS (MPNST)INTENSITY THERAPEUTICS INC - INT230-6 SHOWS COMPLETE RESPONSE IN 21 DAYS IN MPNST STUDYReuters
Mon, Jun 30
23Andme Receives Court Approval For Sale To Ttam Research Institute, A Nonprofit Public Benefit Corporation
23andMe Holding Co MEHCQ.PK:23ANDME RECEIVES COURT APPROVAL FOR SALE TO TTAM RESEARCH INSTITUTE, A NONPROFIT PUBLIC BENEFIT CORPORATION23ANDME HOLDING CO - TTAM TO BUY 23ANDME ASSETS FOR $305 MILLIONReuters
Mon, Jun 30
Eve Air Mobility, Aerosolutions, And Bluenest By Globalvia Sign Letter Of Intent For Up To 50 Evtols And Techcare Services
Eve Holding Inc EVEX.N:EVE AIR MOBILITY, AEROSOLUTIONS, AND BLUENEST BY GLOBALVIA SIGN LETTER OF INTENT FOR UP TO 50 EVTOLS AND TECHCARE SERVICESEVE HOLDING INC - AGREEMENT TO DEVELOP ADVANCED AIR MOBILITY ECOSYSTEM IN COSTA RICAReuters
Mon, Jun 30
Takeda Announces U.S. FDA Approval Of Gammagard Liquid Erc, The Only Ready-To-Use Liquid Immunoglobulin Therapy With Low Immunoglobulin A (Iga) Content1
Takeda Pharmaceutical Co Ltd 4502.T:TAKEDA ANNOUNCES U.S. FDA APPROVAL OF GAMMAGARD LIQUID ERC, THE ONLY READY-TO-USE LIQUID IMMUNOGLOBULIN THERAPY WITH LOW IMMUNOGLOBULIN A (IGA) CONTENT1TAKEDA PHARMACEUTICAL CO LTD - TO DISCONTINUE FIRST-GENERATION LOW-IGA PRODUCTTAKEDA PHARMACEUTICAL CO LTD - GAM...Reuters
Mon, Jun 30
Clene Provides Regulatory Update Following Constructive FDA Type-C Meeting On Neurofilament Biomarker Analysis Plan And Confirms Two Additional FDA Meetings
Clene Inc. CLNN.O:CLENE PROVIDES REGULATORY UPDATE FOLLOWING CONSTRUCTIVE FDA TYPE-C MEETING ON NEUROFILAMENT BIOMARKER ANALYSIS PLAN AND CONFIRMS TWO ADDITIONAL FDA MEETINGSCLENE INC. - CONFIRMS TWO ADDITIONAL FDA MEETINGS FOR Q3 2025CLENE INC. - ON TRACK FOR ALS NDA SUBMISSION IN Q4 2025CLENE INC....Reuters
Mon, Jun 30
WTW and Verisk collaborate to boost efficiency, speed, accuracy, and analytical sophistication in commercial insurance pricing
June 30 (Reuters) - Willis Towers Watson WTW.O:WTW AND VERISK COLLABORATE TO BOOST EFFICIENCY, SPEED, ACCURACY, AND ANALYTICAL SOPHISTICATION IN COMMERCIAL INSURANCE PRICINGReuters
Mon, Jun 30
Revolution Medicines And Summit Therapeutics Enter Into Clinical Collaboration To Evaluate Combinations Of Three Ras(On) Inhibitors With Ivonescimab In Ras Mutant Tumors
Revolution Medicines Inc RVMD.O:REVOLUTION MEDICINES AND SUMMIT THERAPEUTICS ENTER INTO CLINICAL COLLABORATION TO EVALUATE COMBINATIONS OF THREE RAS(ON) INHIBITORS WITH IVONESCIMAB IN RAS MUTANT TUMORSREVOLUTION MEDICINES INC - SUMMIT TO SUPPLY IVONESCIMAB, REVOLUTION MEDICINES TO SPONSOR STUDYReuters
Mon, Jun 30
Biofrontera Inc. Announces Major Restructuring Of Relationship With Biofrontera AG Backed By $11 Million Investment
Biofrontera Inc BFRI.O:BIOFRONTERA INC. ANNOUNCES MAJOR RESTRUCTURING OF RELATIONSHIP WITH BIOFRONTERA AG BACKED BY $11 MILLION INVESTMENTBIOFRONTERA INC - BUYS ALL US ASSETS OF AMELUZ AND RHODOLEDBIOFRONTERA INC - ROYALTY RATE REDUCED TO 12% FROM 25%-35% OF NET SALESBIOFRONTERA INC - BIOFRONTERA ...Reuters
Mon, Jun 30
Catheter Precision, Inc. Forms New Joint Venture Called Kardionav To Exploit Patented Ai Techniques To Create New Vt Software Platform
Catheter Precision Inc VTAK.A:CATHETER PRECISION, INC. FORMS NEW JOINT VENTURE CALLED KARDIONAV TO EXPLOIT PATENTED AI TECHNIQUES TO CREATE NEW VT SOFTWARE PLATFORMReuters
Mon, Jun 30
Corbus Pharmaceuticals Initiates Multiple Ascending Dose Portion Of Phase 1 Study Of Highly Peripherally Restricted Cb1 Inverse Agonist Crb-913 For The Treatment Of Obesity
Corbus Pharmaceuticals Holdings Inc CRBP.O:CORBUS PHARMACEUTICALS INITIATES MULTIPLE ASCENDING DOSE PORTION OF PHASE 1 STUDY OF HIGHLY PERIPHERALLY RESTRICTED CB1 INVERSE AGONIST CRB-913 FOR THE TREATMENT OF OBESITYCORBUS PHARMACEUTICALS HOLDINGS INC - MAD PORTION OF PHASE 1 TRIAL SCHEDULED FOR COMP...Reuters
Mon, Jun 30
